As part of the Cardiology at the Interface of Primary and Secondary Care webinar series, this 90-minute interactive session will explore the evolving landscape of lipid management in cardiovascular disease prevention.
This session will delve into the key role of LDL in the development of atherosclerotic cardiovascular disease, the selection of patients for treatment, and the use of modern therapies to optimise LDL lowering and improve patient outcomes.
This session is RACGP approved for 1.5 hours of Education Activities. It is also accredited with ACCRM, Activity ID: 37672
Learning outcomes:
- Explain the role of dyslipidemia in the development of atherosclerotic cardiovascular disease.
- Evaluate the role of absolute risk assessment in the management of cardiovascular risk.
- To identify contemporary LDL targets in high risk populations
- Describe the treatment options for high-risk dyslipidemia.
Speaker information:
Dr Andrew Black is a senior staff specialist interventional cardiologist at the Royal Hobart Hospital and senior adjunct researcher at the Menzies Institute for Medical Research. Andrew is the clinical lead of the Tasmanian STEMI Network and holds leadership positions with national clinical quality registries for coronary intervention. He is a member of the RACP Advanced Training Committee in Cardiology, the Australian Atherosclerosis Society Expert Advisory Panel and Familial Hypercholesterolemia Australasia Professional Advisory Body.